Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ELLEN R SHER

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1710961602
CMS profile
169183
Location
OCEAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$157,039.37

206 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ELLEN R SHER

NPI 1710961602 · CMS profile ID 169183

Allopathic & Osteopathic Physicians / Allergy & Immunology

OCEAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710961602?year=2022&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ELLEN R SHER, NPI 1710961602, CMS profile ID 169183. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710961602?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ELLEN R SHER, NPI 1710961602, CMS profile ID 169183. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710961602?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ELLEN R SHER, NPI 1710961602, CMS profile ID 169183, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1710961602?year=2022&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

206 matching records · $157,039.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 206 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–206 of 206.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $12.8202/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914732061 CMS
GlaxoSmithKline, LLC. $1,300.0002/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944654795 CMS
AstraZeneca Pharmaceuticals LP $1,200.0001/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914894715 CMS
AstraZeneca Pharmaceuticals LP $12.9901/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915341181 CMS
AstraZeneca Pharmaceuticals LP $2,416.5001/06/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915527769 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.8801/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955993165 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $70,477.75 141
PY2020 $78,787.67 95
PY2021 $116,831.85 135
PY2022 $157,039.37 206
PY2023 $197,595.63 283
PY2024 $175,471.09 248
PY2025 $223,652.36 259

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $209,651.47 14
PY2024 Principal investigator $197,398.25 57
PY2023 Principal investigator $157,840.92 80
PY2022 Principal investigator $160,759.10 22
PY2021 Principal investigator $401,820.51 32
PY2020 Principal investigator $419,670.03 37
PY2019 Recipient $1,193.02 7
PY2019 Principal investigator $182,633.95 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 12/24/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NJ PC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184280312
Principal investigator 1 Novartis Pharmaceuticals Corporation $336.56 10/08/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NEW JERSEY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190301599
Principal investigator 1 Novartis Pharmaceuticals Corporation $140.00 10/01/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NEW JERSEY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190301603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 09/29/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NJ PC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184243559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 08/28/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NJ PC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184232854
Principal investigator 1 Eli Lilly and Company $16,810.31 08/01/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NJ
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187876275
Principal investigator 1 Novartis Pharmaceuticals Corporation $180.50 08/01/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NEW JERSEY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190301601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 07/02/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NJ PC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 07/02/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NJ PC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $430.10 05/19/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NJ PC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196351
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,100.20 04/30/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NEW JERSEY, P.C
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185540403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $430.10 02/27/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NJ PC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184155832
Principal investigator 1 AstraZeneca Pharmaceuticals LP $122,275.40 02/26/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NEW JERSEY, P.C
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) No dispute reported 06/30/2026 1185540405
Principal investigator 1 AstraZeneca UK Limited $59,136.75 02/13/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NJ PC
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185540401